668 related articles for article (PubMed ID: 17618131)
1. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice.
Bootsma HP; Aldenkamp AP; Diepman L; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M
Epilepsia; 2006; 47 Suppl 2():24-7. PubMed ID: 17105455
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
[TBL] [Abstract][Full Text] [Related]
4. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Bootsma HP; Coolen F; Aldenkamp AP; Arends J; Diepman L; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M
Epilepsy Behav; 2004 Jun; 5(3):380-7. PubMed ID: 15145308
[TBL] [Abstract][Full Text] [Related]
5. The impact of side effects on long-term retention in three new antiepileptic drugs.
Bootsma HP; Ricker L; Hekster YA; Hulsman J; Lambrechts D; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
Seizure; 2009 Jun; 18(5):327-31. PubMed ID: 19110447
[TBL] [Abstract][Full Text] [Related]
6. Three-Year Retention Rates of Levetiracetam, Topiramate, and Oxcarbazepine: A Retrospective Hospital-Based Study.
Sunwoo JS; Park BS; Ahn SJ; Hwang S; Park CY; Jun JS; Kim DW; Lee ST; Jung KH; Park KI; Chu K; Jung KY; Lee SK
Clin Neuropharmacol; 2017; 40(2):56-62. PubMed ID: 28118167
[TBL] [Abstract][Full Text] [Related]
7. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy.
Kim DW; Lee SY; Shon YM; Kim JH
Epilepsia; 2013 Oct; 54(10):e146-9. PubMed ID: 23980720
[TBL] [Abstract][Full Text] [Related]
8. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.
Mula M; Trimble MR; Sander JW
Epilepsia; 2007 Dec; 48(12):2322-6. PubMed ID: 17711462
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and tolerability of topiramate, lamotrigine, and levetiracetam in children with refractory epilepsy].
Kato T; Nakata M; Ide M; Saito K; Yoshida T; Awaya T; Heike T
No To Hattatsu; 2015 Sep; 47(5):354-9. PubMed ID: 26502652
[TBL] [Abstract][Full Text] [Related]
10. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy.
Huang CW; Pai MC; Tsai JJ
Psychiatry Clin Neurosci; 2008 Oct; 62(5):548-53. PubMed ID: 18950374
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?
Zaccara G; Messori A; Cincotta M; Burchini G
Acta Neurol Scand; 2006 Sep; 114(3):157-68. PubMed ID: 16911343
[TBL] [Abstract][Full Text] [Related]
12. Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam.
Roberts GM; Majoie HJ; Leenen LA; Bootsma HP; Kessels AG; Aldenkamp AP; Leonard BE
Epilepsy Behav; 2005 May; 6(3):366-72. PubMed ID: 15820345
[TBL] [Abstract][Full Text] [Related]
13. Comparative retention rates and long-term tolerability of new antiepileptic drugs.
Chung S; Wang N; Hank N
Seizure; 2007 Jun; 16(4):296-304. PubMed ID: 17267243
[TBL] [Abstract][Full Text] [Related]
14. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany.
Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E
Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573
[TBL] [Abstract][Full Text] [Related]
15. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate.
Gomer B; Wagner K; Frings L; Saar J; Carius A; Härle M; Steinhoff BJ; Schulze-Bonhage A
Epilepsy Behav; 2007 May; 10(3):486-94. PubMed ID: 17409025
[TBL] [Abstract][Full Text] [Related]
16. Retention rate of levetiracetam in children with intractable epilepsy at 1 year.
Peake D; Mordekar S; Gosalakkal J; Mukhtyar B; Buch S; Crane J; Wheway R; Rittey C; Donnelly J; Whitehouse WP; Philip S
Seizure; 2007 Mar; 16(2):185-9. PubMed ID: 17258474
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
von Stuelpnagel C; Holthausen H; Kluger G
Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601
[TBL] [Abstract][Full Text] [Related]
18. Long-term Effectiveness of Antiepileptic Drug Monotherapy in Partial Epileptic Patients: A 7-year Study in an Epilepsy Center in China.
Zhu F; Lang SY; Wang XQ; Shi XB; Ma YF; Zhang X; Chen YN; Zhang JT
Chin Med J (Engl); 2015 Nov; 128(22):3015-22. PubMed ID: 26608980
[TBL] [Abstract][Full Text] [Related]
19. Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?
Brodie MJ; Kelly K; Stephen LJ
Epilepsy Behav; 2014 Feb; 31():73-6. PubMed ID: 24361766
[TBL] [Abstract][Full Text] [Related]
20. New antiepileptic drugs in practice--how do they perform in the real world?
Sander JW
Acta Neurol Scand Suppl; 2005; 181():26-9. PubMed ID: 16238705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
